• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 21st May 2023

Setting the Right Discount Rate for HTA in the Slovak Republic

Health interventions such as new medicines produce costs and health-related effects not only in the year they are introduced but in all future years until they are discontinued. People generally care less about future outcomes (for example, having better health…

Jake 3
Jake Hitch
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Slovak discounting_andrik-langfield-0rTCXZM7Xfo-unsplash_landscape

Health interventions such as new medicines produce costs and health-related effects not only in the year they are introduced but in all future years until they are discontinued. People generally care less about future outcomes (for example, having better health today is generally preferred to having better health in 10 years’ time). To reflect this, health economic evaluations value present outcomes more than future outcomes. The extent to which present outcomes are valued more than future outcomes is represented by the discount rate.

Following a request from the Association of Innovative Pharmaceutical Industry in the Slovak Republic (AIFP), a member of EFPIA, the Office of Health Economics (OHE) accepted the challenge of estimating the most appropriate, up-to-date discount rate, underpinned by the strongest rationale across the different approaches for potential use in health technology assessment (HTA) in the Slovak Republic.

For this purpose, we estimated the country-specific social rate of time preference, a common method for setting discount rates for economic evaluation of public investments. We used the best available official macroeconomic and demographic data. Based on our analysis, we have formulated seven recommendations to the relevant departments of the Slovak government, and we summarise the four most relevant ones below.

Lower the discount rate for use in reference case health economic evaluations from 5% to 3.3% per year.

We estimate that the social rate of time preference for the Slovak Republic is currently 3.3% per year, contrasting with the 5% discount rate currently required for pharmacoeconomic analysis. The discrepancy between the two rates comes in the estimate for expected growth in consumption over time. We argue that our estimate is more suitable given the current economic and demographic characteristics of the Central European country.

Explore whether a lower discount rate should be used for health effects compared to costs (differential discounting).

Economic theory suggests that under certain circumstances it is appropriate to use a lower discount rate for health effects than costs if the opportunity cost of new health investment (reimbursing a new drug for example) is expected to increase over time. Differential discounting may also be appropriate if the consumption value of health (the rate at which society is willing to trade consumption for health) is expected to increase over time. Further research is required to estimate these two parameters for the Slovak Republic and therefore to determine whether differential discounting is appropriate.

Increase transparency around the choice of discounting method and rate(s) for use in HTA.

HTA agencies’ choice of discounting method and rate(s) should be based on accepted economic theory and the best available data. HTA agencies need to be transparent about their chosen discounting methods so that they can be evaluated. HTA agencies should ideally collaborate with relevant government departments such as finance departments and statistical offices to produce rigorous and consistent estimates of the key parameters of discount rate models, such as the Ramsey Rule which we use in our analysis.

Continue to update the discount rate every four to five years in line with updates to HTA methods guides in other countries.

The rates at which people are willing to trade present consumption or health for future consumption or health understandably change with macroeconomic and demographic conditions. HTA agencies should regularly repopulate the relevant equations behind their discount rates with the most recent data and update their official discount rates when necessary.

While our discount rate estimate is specific to the Slovak Republic, many of the recommendations contain important considerations that all HTA agencies incorporating economic evaluation in their methods should consider when setting a discount rate.

To read the full report containing the full set of recommendations and details of our analysis, click here.

 

Citations

Hitch J., Berdud M., Cubi-Molla P., Garau M., Towse A., 2023. Setting the right discount rate for health technology assessment in the Slovak Republic. OHE Consulting Report. Available from: https://www.aifp.sk/sk/media-a-verejnost/69/spravne-nastavenie-diskontnych-sadzieb-v-ramci-hta-setting-the-proper-discount-rate-for-health-technology-assessment/

  • Health Technology Assessment…
  • Value, Affordability, and…
  • HTA

Related Insights

HTA Slovak Republic-1
  • Insight
  • September 2023

Around The World in HTAs: The Slovak Republic – Valuing the Future

Read more
this one
  • Insight
  • July 2023

Around The World in HTAs: Egypt – The Road Ahead

Read more
india-balloon-2921973 v3
  • Insight
  • June 2023

Around The World in HTAs: India – Let All Be Healthy

Read more
RWB Netherlands air balloon_landscape
  • Insight
  • May 2023

Around The World in HTAs: The Netherlands – 5 Routes for New Tech

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!